Novozymes A/S (OTCMKTS:NVZMY) Short Interest Up 253.0% in May

Novozymes A/S (OTCMKTS:NVZMY) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totaling 30,830 shares, a growth of 253.0% from the April 30th total of 8,733 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 92,688 shares, the short-interest ratio is presently 0.3 days.

Novozymes A/S Stock Down 2.0%

Shares of NVZMY stock traded down $1.19 during trading hours on Friday, reaching $57.83. 46,197 shares of the stock were exchanged, compared to its average volume of 43,532. The business’s fifty day moving average is $59.17 and its two-hundred day moving average is $60.79. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.67 and a quick ratio of 0.44. Novozymes A/S has a 12-month low of $49.90 and a 12-month high of $75.99. The firm has a market capitalization of $23.97 billion, a P/E ratio of 39.07, a P/E/G ratio of 1.11 and a beta of 0.98.

Novozymes A/S (OTCMKTS:NVZMY) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). Novozymes A/S had a return on equity of 6.52% and a net margin of 14.22%.The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.32 billion. As a group, research analysts expect that Novozymes A/S will post 2.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Zacks Research lowered shares of Novozymes A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, May 4th. Rothschild & Co Redburn upgraded shares of Novozymes A/S to a “strong-buy” rating in a research note on Friday, March 27th. Finally, Kepler Capital Markets raised Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy”.

About Novozymes A/S

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).